Related Experiment Video
Updated: Jun 29, 2026
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
Radioimmunotherapy of brain tumor
Giovanni Paganelli1, Mirco Bartolomei, Chiara Grana
1Division of Nuclear Medicine, European Institute of Oncology, Milano, Italy.
Abstract:
Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pre-targeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.
Insights
Radioimmunotherapy (RIT) using monoclonal antibodies (MoAbs) and avidin-biotin pre-targeting offers a promising strategy to improve high-grade glioma treatment. This approach enhances tumor cell irradiation specificity for better patient prognosis.
Area of Science:
- Oncology
- Immunotherapy
- Radiochemistry
Background:
- High-grade gliomas (HGG) exhibit poor prognosis and resistance to conventional therapies.
- Novel therapeutic strategies are crucial for improving treatment outcomes in HGG.
- Monoclonal antibodies (MoAbs) combined with radioisotopes show potential for targeted cancer treatment.
Purpose of the Study:
- To describe the experience with radioimmunotherapy (RIT) for high-grade gliomas.
- To evaluate the efficacy of MoAbs and avidin-biotin pre-targeting in RIT.
- To explore both systemic and locoregional administration of RIT.
Main Methods:
- Utilized monoclonal antibodies (MoAbs) for targeted delivery of radioisotopes.
- Employed the avidin-biotin system for tumor pre-targeting to enhance specificity.
- Administered RIT via both systemic and locoregional routes.
Main Results:
- RIT with MoAbs and avidin-biotin pre-targeting demonstrated increased specificity in tumor cell irradiation.
- The described RIT approach offers potential for improved therapeutic responses in HGG.
- Both systemic and locoregional administrations were explored.
Conclusions:
- Radioimmunotherapy (RIT) presents a promising avenue for treating high-grade gliomas.
- Combining RIT with surgery, radiotherapy, and chemotherapy may enhance treatment efficacy.
- Further integration of RIT into multimodal treatment strategies is recommended.
